emer gency with de creased level of conscious ness. Af ter a stay in the car diac care unit, he re cov ered fully. Fol low ing re cov ery, Mr A re ported that he had found the chlo ral hy drate in ef fec tive and had re sorted to us ing in creas ingly large doses for sev eral weeks prior to his over dose.
Allan Frankland, MD, Resident Michael J Robinson, MD, FRCPC Kingston, Ontario
Gabapentin Use in Geriatric Patients With Depression and Bipolar Illness

Dear Edi tor:
There are sev eral stud ies of ga bap en tin us age for pa tients with de pres sion and bi po lar ill ness (1) (2) (3) (4) (5) , but there is lit tle pub lished on geri at ric pa tients. We wish to re port on an open-label trial in which ga bap en tin was added to the regi men of 5 geri at ric pa tients with de pres sion and bi po lar ill ness. These pa tients were on lith ium and val proate and had failed to im prove on a trial of 2 an ti de pres sants.
Pa tients for this study were over age 65 years and had a di ag no sis of bi po lar mood dis or der, based on DSM-IV cri teria. There were no ex clu sion cri te ria. This trial of ga bap en tin was given to the first 5 con secu tive pa tients ad mit ted to the in pa tient unit. The pa tients had been on both lith ium and val proate for at least 3 months prior to the study. Ga bap en tin was added be cause their de pres sive episodes had not re sponded to a 2-month trial of ser tra line fol lowed by a fur ther 2-month trial of nor trip tyline. We obtained in formed con sent from both patient and fam ily. Ga bap en tin was started at a dos age of 300 mg at bed time and on the fourth day in creased to 300 mg every morn ing and at bed time. Im prove ment was meas ured by clini cal in ter view and Ham il ton De pres sion Rat ing Scale (HDRS), ad min is terd by the same psy chia trist.
The study group con tained 3 women and 2 men. The av er age age was 73.2 years (range 65 to 85 years). The av er age score on the HDRS at the be gin ning of the study was 30.8 (range, 25 to 35). Four of the pa tients had the rapid-cycling subtype of bi po lar dis or der, and the other pa tient had the mixed-state sub type.
Of the 5 who were given ga bap en tin, 1 woman with a mixed state had re mis sion of her de pres sive epi sode as judged by clini cal in ter view and a de crease in HDRS score from 25 to 6. When she had a re lapse a few months later, her mood im proved when the ga bap en tin dos age was in creased from 300 mg twice daily to 300 mg three times daily. Over the course of 6 months of follow-up, however, she has had more fre quent epi sodes of mood dis or der (both de pres sion and hy po ma nia) while tak ing ga bap en tin. Ga bap en tin ap peared to be well tol erated by all 5 pa tients, but 2 did com plain of head ache, al though this ac tu ally seemed to be more of a chronic prob lem for these pa tients, even be fore the trial. Se da tion did not be come a prob lem for any of these 5 pa tients.
Al though the ga bap en tin was well tol erated by pa tients in this study, it did not seem to pro vide much ad di tional bene fit to pa tients with de pres sion and bi po lar ill ness who were tak ing both lith ium and val proate. It is pos si ble that in this study the dos age of ga bap en tin was too low and that the length of time was too short.
From this small case se ries it is clear that the man age ment of elder pa tients with re frac tory rapid-cycling or mixed subtype of bi po lar ill ness re mains a challenge. Skep ti cism and cau tion are war ranted in in ter pret ing the re sults of an open, small, un con trolled case se ries: po ten tial un in ten tional bias, pla cebo response, and ran dom vari abil ity can lead to false-positive re sults. Thus, the methodo logi cal limi ta tions of this study highlight the need for ran dom ized con trolled tri als.
